Serum lipoprotein(a) is not modified by interleukin-6 receptor antagonism or associated with inflammation in non-ST-elevation myocardial infarction

The IL-6 receptor antagonist tocilizumab has been shown to attenuate the proatherogenic lipoprotein a [Lp(a)] in rheumatoid arthritis. We evaluated if a single dose of tocilizumab reduced Lp(a) in patients with non-ST-elevation myocardial infarction (NSTEMI).

Source: International Journal of Cardiology - June 22, 2018 Category: Cardiology Authors: Thor Ueland, Ola Kleveland, Annika E. Michelsen, Rune Wiseth, Jan Kristian Dam ås, Kirsten B. Holven, Pål Aukrust, Lars Gullestad, Arne Yndestad, Bente Halvorsen Tags: Short communication Source Type: research